Eloxx Pharmaceuticals Raises $6M

Rehovat, Israel-based Eloxx Pharmaceuticals, which is a wholly owned subsidiary of San Diego-based Sevion Therapeutics, said it ha raised $6M as part of a Series C funding round. The funding came from Korea Investment Partners (KIP) and DSC Investments, and is part of the acquisition deal between Sevion and Eloxx. The companies said that Eloxx has now raised $30M in its Series C funding. Eloxx is developing drugs to treat genetic diseases, including Cystic Fibrosis (CF), Cystinosis, Duchene Muscular Dystrophy (DMD), Rett syndrome and mucopolysaccharidose type I (MPS I).